[China Biologic Products, Inc. 8th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China February 25, 2016 VIA EDGAR 100 F Street, N.E. Re: Notice of Disclosure Filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the]
[Annual Report on Form 10-K Year Ended December 31, 2015 TABLE OF CONTENTS PART I Item 1. Business 3 Item 1A. Risk Factors 24 Item 1B. Unresolved Staff Comments 45 Item 2. Properties 45 Item 3. Legal Proceedings 46 Item 4. Mine Safety Disclosures 48 PART II Item 5. 49 Item 6. Selected Financial Data 50 Item 7. Management’s Discussion] [CHINA BIOLOGIC PRODUCTS, INC. The subsidiaries of China Biologic Products, Inc. are as follows: Jurisdiction of Name Incorporation or Organization Ownership Interest Taibang Biological Ltd. BVI 100.0% Taibang Holdings (Hong Kong) Limited HK 100.0% Taibang Biotech (Shandong) Co., Ltd. Shandong PRC 100.0% Taibang (Beijing) Pharmaceutical Research Institute Co., Ltd. Beijing PRC 100.0% Shandong Taibang Biological Products Co., Ltd. Shandong PRC] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in the registration statement (No. 333-204761) on Form S-3 and the registration statement (No. 333-151263) on Form S-8 of China Biologic Products, Inc. of our reports dated February 25, 2016, with respect to the consolidated balance sheets of China Biologic Products, Inc.] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial and Accounting Officer)]
[Annual Report on Form 10-K Year Ended December 31, 2015 TABLE OF CONTENTS PART I Item 1. Business 3 Item 1A. Risk Factors 24 Item 1B. Unresolved Staff Comments 45 Item 2. Properties 45 Item 3. Legal Proceedings 46 Item 4. Mine Safety Disclosures 48 PART II Item 5. 49 Item 6. Selected Financial Data 50 Item 7. Management’s Discussion] [CHINA BIOLOGIC PRODUCTS, INC. The subsidiaries of China Biologic Products, Inc. are as follows: Jurisdiction of Name Incorporation or Organization Ownership Interest Taibang Biological Ltd. BVI 100.0% Taibang Holdings (Hong Kong) Limited HK 100.0% Taibang Biotech (Shandong) Co., Ltd. Shandong PRC 100.0% Taibang (Beijing) Pharmaceutical Research Institute Co., Ltd. Beijing PRC 100.0% Shandong Taibang Biological Products Co., Ltd. Shandong PRC] [Consent of Independent Registered Public Accounting Firm The Board of Directors We consent to the incorporation by reference in the registration statement (No. 333-204761) on Form S-3 and the registration statement (No. 333-151263) on Form S-8 of China Biologic Products, Inc. of our reports dated February 25, 2016, with respect to the consolidated balance sheets of China Biologic Products, Inc.] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this annual report on Form 10-K of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial and Accounting Officer)]
[CHINA BIOLOGIC PRODUCTS, INC. AMENDED AND RESTATED DIRECTOR AGREEMENT Agreement Company Mr. David Li Director THIS AGREEMENT (this “ BACKGROUND Original Agreement The Director and the Company entered into a director agreement (the “ The Director and the Company desire to enter into this Agreement to amend and restate the Original Agreement in its entirety. AGREEMENT In consideration for the] [FOR RELEASE February 25, 2016 China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2015 4Q15 Total Sales Up 22.6% with Non-GAAP Net Income Up 44.5% YoY in RMB terms, or Up 17.8% YoY to $68.3 Million and 38.8% YoY to $20.4 Million in USD terms, respectively FY15 Total Sales Up 23.4% with Non-GAAP Net Income Up] []
[CHINA BIOLOGIC PRODUCTS, INC. AMENDED AND RESTATED DIRECTOR AGREEMENT Agreement Company Mr. David Li Director THIS AGREEMENT (this “ BACKGROUND Original Agreement The Director and the Company entered into a director agreement (the “ The Director and the Company desire to enter into this Agreement to amend and restate the Original Agreement in its entirety. AGREEMENT In consideration for the] [FOR RELEASE February 25, 2016 China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2015 4Q15 Total Sales Up 22.6% with Non-GAAP Net Income Up 44.5% YoY in RMB terms, or Up 17.8% YoY to $68.3 Million and 38.8% YoY to $20.4 Million in USD terms, respectively FY15 Total Sales Up 23.4% with Non-GAAP Net Income Up] []
[China Biologic Products, Inc. 8th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People’s Republic of China February 25, 2016 VIA EDGAR 100 F Street, N.E. Re: Notice of Disclosure Filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the]
[1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Capital World Investors ** 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware 5 SOLE VOTING POWER 1,833,294 6 SHARED VOTING POWER NUMBER OF SHARES NONE BENEFICIALL Y OWNED BY]
[1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Capital World Investors ** 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) (b) 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware 5 SOLE VOTING POWER 1,833,294 6 SHARED VOTING POWER NUMBER OF SHARES NONE BENEFICIALL Y OWNED BY]
[Common Stock 16938C106 December 31, 2015 ☐ Rule 13d-1(b) ☑ Rule 13d-1(c) ☐ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.]
[Common Stock 16938C106 December 31, 2015 ☐ Rule 13d-1(b) ☑ Rule 13d-1(c) ☐ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.]
